Skip to content
Join free
Back

Supplements & PeptidesOn or considering GLP-1s

The scale can fall while lean mass falls too

In a scan subset of a large weight-loss trial, fat fell faster than lean mass, and lean mass still fell. Lifting during the medicine is a reasonable question these papers did not answer.

Checked against the sources ยท Updated 17 Nov 2026

In short

  • In the STEP 1 body-composition subset, semaglutide lowered fat more than it lowered lean mass, and lean mass still fell in kilograms. A randomized test of lifting during these medicines was not opened.
  • One large weight-loss trial and its 140-person scan subset show fat loss plus a real drop in absolute lean mass. They do not test whether strength training prevents that drop.

The scale can fall while lean mass falls too

The grocery bag was not this heavy on the stairs last month. Or maybe it was, and you are only noticing now, because the scale in the bathroom has been moving the other way and the bag did not get the memo. If you are on a GLP-1 medicine, or sitting with the question of one, that mismatch is worth a calm look, and it does not need to become a scare.

These medicines can take weight off, and a share of what leaves can be lean tissue. That is the finding to hold. It is not a reason to skip a medicine your clinician prescribed, and it is not proof that a gym plan will block the loss. The medicines are prescription only. No dose is given here. The weekly amount used in the trial stays in the paper.

What the large trial measured

STEP 1, published in 2021 in the New England Journal of Medicine, assigned 1,961 adults without diabetes to once-weekly semaglutide or to a placebo. Both groups also followed a lifestyle program, and the trial ran 68 weeks. People could enter with overweight or obesity.

Mean weight change was 14.9% down with semaglutide and 2.4% down with placebo. That is a weight result, from a trial that assigned the medicine by chance, against a look-alike. It is not a picture of what the lost weight was made of. For that, the trial looked at a smaller group.

What the scans showed

A subset of 140 people had DXA scans, the kind of body scan that separates fat from lean tissue. They were eligible if body mass index was 40 or under. These results come from an exploratory look at STEP 1, published as a meeting abstract rather than as a full paper of its own. The numbers are real in that abstract. A short report is also a reason to hold them carefully.

On semaglutide, total fat mass in this subset fell about 19.3%. Total lean mass fell about 9.7% from its own starting point. Fat left faster than lean tissue did, so lean mass as a share of body weight rose by about 3.0 percentage points. A higher share of a smaller body is not the same thing as keeping the kilograms of lean tissue you started with. The placebo scans barely moved. If the bag on the stairs is the question you came in with, the scans are why the question is fair. They are not a measurement of your stairs.

What the stomach effects have to do with strength

Side effects in the full trial were mostly in the stomach and gut. Nausea was reported by 44.2% of people on semaglutide and 17.4% on placebo. People stopped the assigned regimen because of gut events at 4.5% versus 0.8%. Most of those events were mild or moderate and eased. That is the trial's account, not a forecast for you. It is also a reason the scale is not the only thing worth watching. If eating becomes difficult, strength is not having an ordinary week.

The training question these papers do not answer

The lifestyle program in STEP 1 was in both groups. It was not a comparison of lifting versus not lifting. No finished trial here tests whether strength training during semaglutide or tirzepatide prevents the lean-mass drop, so there is no result to borrow on that question.

Whether these products are registered with the Philippine FDA is not answered here. A small before-and-after gym report is not part of this evidence. A clinician, not an article, is who starts, stops, or changes a prescription medicine.

What to ask, if you are already on one

The scans give you a reason to ask. They do not hand you a program.

  • Ask how strength will be checked, not only the scale. A grip reading, or a sit-to-stand, repeated the same way each time, is a track you can keep with your clinician. The point is the same test twice, so a change is a change and not a different gadget.
  • Keep some strength work in the week if your clinician is fine with it. That is a precaution drawn from the lean-mass drop in the scans. It is not a result from a trial of lifting on the medicine.
  • Leave the dose where it belongs. Nothing here is a weekly amount to copy. If the medicine is in your life, the person who prescribed it is the person who adjusts it.

The bag on the stairs is a fair question to carry into the clinic. It is a poor reason to rewrite the prescription on the landing.

When strength falling is a reason to be seen

Be seen if you cannot keep food down, if you are dizzy, or if everyday strength is falling faster than the clinic expected. Those are reasons to be seen, and they are not reasons to change a dose yourself. Bring the practical detail, the meals you cannot finish or the stairs that changed, and let the clinician decide what the medicine should do next. The scans explain why strength belongs in that conversation. They do not replace it.

---

Sources

  • Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021. https://doi.org/10.1056/NEJMoa2032183
  • Wilding JPH, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. Journal of the Endocrine Society. 2021. https://doi.org/10.1210/jendso/bvab048.030

General guidance, not medical advice or a diagnosis. Talk with your doctor about your own health.

How strong is the evidence?

Prescription only

What the research says: Gastrointestinal events were more common on semaglutide, 74.2% versus 47.9%. Nausea was 44.2% versus 17.4%. Stopping for gastrointestinal events was 4.5% versus 0.8%. The main paper says the scans suggested more fat loss than lean-mass loss. Recruiting trials of resistance exercise during semaglutide or tirzepatide have no results in this draft.

What it doesn't say: This does not prescribe a dose. The weekly amount used in STEP 1 stays in the paper, not as a Flamel instruction. It does not say lifting has been shown to save muscle during these medicines. Philippine FDA registration was not checked. A before-and-after gym study of 11 people was not opened and is not cited.

Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.

How we rate: the Flamel Method

Try this

  • If you and your clinician are using one of these medicines, ask how strength will be checked, not only the scale. A grip reading or a sit-to-stand, repeated the same way, is a track you can keep.
  • Keep some strength work in the week if your clinician is fine with it. That is a precaution drawn from what the scans show, the lean-mass drop, and not from a trial of lifting versus no lifting on the medicine.

That counts.

See a doctor if You cannot keep food down, you are dizzy, or everyday strength is falling faster than the clinic expected. Those are reasons to be seen, not reasons to adjust a dose yourself.

Get delightful living tips directly in your email

Join free

Keep reading

Sources

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
  2. Wilding JPH, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. Journal of the Endocrine Society. 2021.

Last reviewed by Flamel Staff on 17 Nov 2026

Flamel is not medical advice and does not diagnose. If you have symptoms or readings in the red zone, see a doctor.